ACell Launches Roadshow for Initial Public Offering

COLUMBIA, Md., July 13, 2020 /PRNewswire/ -- ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has launched the roadshow for the initial public offering of its common stock. ACell is offering 5,000,000 shares of its common stock at an expected initial public offering price between $14.00 and $16.00 per share. ACell expects certain selling stockholders to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions. ACell has applied to list its common stock on the Nasdaq Global Market under the ticker symbol "ACLL."

The offering is being made through an underwriting group led by UBS Investment Bank, Barclays and RBC Capital Markets who are acting as lead bookrunning managers, and SunTrust Robinson Humphrey who is acting as joint bookrunning manager.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by e-mail at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847 or by email at [email protected]; or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281, Attention: Equity Syndicate Department, by telephone at 1-877-822-4089, or by e-mail at [email protected].

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the "SEC") but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of ACell's common stock in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About ACell, Inc.

ACell, Inc. is a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. ACell's products utilize its proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body's ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue.

Forward-Looking Statements

This press release includes certain disclosures which contain "forward-looking statements," including, without limitation, statements regarding ACell's expectation with respect to the option granted to the underwriters by certain selling stockholders.  Forward-looking statements are based on ACell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.  Factors that could cause actual results to differ include, but are not limited to, market conditions, risks and uncertainties related the satisfaction of customary closing conditions related to, and the completion of, the public offering.  Many of these factors are beyond ACell's control.  These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the preliminary prospectus related to the public offering filed with the SEC.  Forward-looking statements contained in this announcement are made as of this date, and ACell undertakes no duty to update such information except as required under applicable law.

SOURCE ACell, Inc.

Related Links

http://www.acell.com